Retinal pigment epithelial cell replacement therapy (Cell Cure Neurosciences)

36-Month Results of OpRegen Cell Therapy for Geographic Atrophy to Be Presented at CTS 2025

11 days ago

• Long-term 36-month data from the Phase 1/2a trial of RG6501 (OpRegen) for geographic atrophy secondary to AMD will be presented at Clinical Trials at the Summit in June 2025. • OpRegen, an allogeneic retinal pigment epithelial cell therapy developed by Lineage Cell Therapeutics in collaboration with Roche and Genentech, aims to counteract RPE cell loss in geographic atrophy. • The therapy is currently advancing in a separate Phase 2a clinical study, potentially offering a novel treatment approach for geographic atrophy, a leading cause of adult blindness affecting over 5 million people globally.

Dry AMD Therapeutic Pipeline Shows Promise with 70+ Companies Advancing Novel Therapies

4 months ago

• The dry age-related macular degeneration (AMD) therapeutic landscape is robust, with over 70 companies developing more than 80 therapies. • Key companies like Alkeus Pharmaceuticals and Roche are evaluating new drugs, aiming to improve the treatment options for dry AMD. • Recent clinical trials show promise, with Ocugen reporting positive data for OCU410 and Eyestem Research achieving a milestone in cell therapy for geographic atrophy. • Several therapies, including gene therapies and complement inhibitors, are in various clinical trial phases, addressing the unmet needs in dry AMD treatment.

Lineage Cell Therapeutics Updates Shareholders on Progress and 2025 Outlook

5 months ago

Lineage Cell Therapeutics, a clinical-stage biotechnology company, has shared a letter with its stockholders detailing recent achievements, including advancements in its allogeneic cell therapy programs, and outlining its outlook for 2025. The company emphasizes its unique approach to cell transplantation, its financial strategy, manufacturing capabilities, and long-term goals, particularly focusing on its OpRegen® program for dry-AMD and other neurological cell transplant candidates.

Emerging Therapies Offer Hope for Geographic Atrophy Treatment

6 months ago

• Several therapies are under evaluation in clinical trials for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), addressing the unmet need for effective treatments. • Complement pathway inhibitors like ANX007, danicopan, and AVD-104 are being investigated to modulate the inflammatory response and cell lysis associated with GA progression. • Gene therapies such as JNJ-1887 and cell-based therapies like ASP7317 and RG6501 are showing promise in protecting retinal cells and improving visual function in GA patients. • Antioxidants like elamipretide, glideuretinal, and AREDS2 supplements are also being explored for their potential to reduce GA lesion progression and improve visual outcomes.

RG6501 Shows Rapid Improvement in Retinal Structure for Geographic Atrophy Patients

2 years ago

• Phase 1/2a trial results for RG6501 (OpRegen) demonstrate significant improvements in outer retinal structure within three months of a single administration in patients with geographic atrophy secondary to AMD. • All five patients in cohort 4 with extensive coverage of GA lesions showed structural improvements and achieved an average 12.8 letter BCVA gain by one year compared to baseline. • The cell therapy, developed through a collaboration between Lineage Cell Therapeutics, Roche, and Genentech, works by delivering allogeneic retinal pigmented epithelial cells to support remaining retinal cells in atrophic areas.